Regeneron Pharmaceuticals (REGN) Other Non Operating Income (2013 - 2026)

Regeneron Pharmaceuticals' Other Non Operating Income history runs 14 years deep, the most recent figure standing at $201.2 million for Q1 2026.

• In Q1 2026, Other Non Operating Income fell 37.52% year-over-year to $201.2 million; the TTM figure through Mar 2026 stood at $1.6 billion (up 31.21% YoY), while the FY2025 annual figure was $1.7 billion, up 100.92% from the prior year.
• Other Non Operating Income was $201.2 million for Q1 2026 at Regeneron Pharmaceuticals, up from $176.0 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $755.8 million in Q3 2025 to a low of -$183.8 million in Q1 2022.
• Historically, Other Non Operating Income has averaged $185.1 million across 5 years, with a median of $193.0 million in 2023.
• Biggest YoY gain for Other Non Operating Income was 1937.8% in 2022; the steepest drop was 218.66% in 2022.
• A 5-year view of Other Non Operating Income shows it stood at $195.3 million in 2022, then retreated by 1.18% to $193.0 million in 2023, then tumbled by 111.19% to -$21.6 million in 2024, then soared by 914.81% to $176.0 million in 2025, then climbed by 14.32% to $201.2 million in 2026.
• The last three Other Non Operating Income figures came in at $201.2 million (Q1 2026), $176.0 million (Q4 2025), and $755.8 million (Q3 2025), per Business Quant data.